All In Biotech

Drug Trial Radar · NCT03440450

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Actual

Start

Mar 22, 2018

Primary completion

Oct 2026

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Feb 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors including biliary tract cancer

Conditions

  • Advanced Solid Tumors
  • Biliary Tract Cancer

Interventions

  • FF-10832 Gemcitabine Liposome InjectionDrug

    FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 30 to 120 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine incidence of Treatment Emergent Adverse Events (TEAE)Time frame: 2.5 years
  2. Identify dose-limiting toxicities (DLT) of FF-10832Time frame: 2.5 years
  3. Determine maximun tolerated dose (MTD) of FF-10832Time frame: 2.5 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona

  • University of Arizona Cancer Center

    Tucson, Arizona

  • Hoag Memorial Hospital Comprehensive Cancer Center

    Newport Beach, California

  • Sarah Cannon Research Institute

    Denver, Colorado

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson Cancer Research Center

    Houston, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.